GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,905 | 2,621 | 5,321 | 2,458 | 4,044 |
| Other current assets | 634 | 760 | 760 | 0 | 0 |
| TOTAL | $8,106 | $4,321 | $7,124 | $2,658 | $4,232 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $8,106 | $4,321 | $7,124 | $2,658 | $4,232 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 748 | 769 | 1,374 | 2,380 | 3,853 |
| Accrued Expenses | 1,560 | 400 | 608 | 1,132 | 1,797 |
| Other current liabilities | 11 | 8 | 28,976 | 126 | 252 |
| TOTAL | $2,319 | $1,321 | $31,043 | $3,638 | $5,902 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 1,956 | 0 | 0 |
| TOTAL | $N/A | $N/A | $1,956 | $N/A | $N/A |
| Total Liabilities | $2,319 | $1,321 | $32,999 | $3,638 | $5,902 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 31,554 | 10,636 | 3,558 | 2,586 | 2,234 |
| Common Shares | 26 | 6 | 3 | 3 | 2 |
| Retained earnings | -723,901 | -718,102 | -726,257 | -696,003 | -695,227 |
| Other shareholders' equity | 1 | 1 | 1 | 1 | 1 |
| TOTAL | $5,787 | $3,000 | $-25,875 | $-980 | $-1,670 |
| Total Liabilities And Equity | $8,106 | $4,321 | $7,124 | $2,658 | $4,232 |